CAR-T Crosses the Blood Cancer Divide: China Approves First Cell Therapy for Solid Tumors, satri-cel

CAR-T therapies have transformed the treatment of some hematologic malignancies, but have consistently struggled to replicate those results in solid tumors. China’s approval of CARsgen Therapeutics’ satri-cel therefore not only adds a treatment option for gastric cancer, but also establishes the first regulatory milestone for cell therapy crossing beyond blood cancers.

China’s National Medical Products Administration (NMPA) approved satri-cel through the priority review pathway on June 22. It is indicated for patients with CLDN18.2-positive, HER2-negative, unresectable advanced gastric adenocarcinoma or gastroesophageal-junction adenocarcinoma whose disease has progressed after at least two lines of therapy. This restriction also underscores that it is not a CAR-T product broadly applicable to all gastric cancers or solid tumors, but a treatment based on precise biomarker selection.

Satri-cel is an autologous CAR-T therapy that uses a humanized receptor to recognize CLDN18.2. The medical team must first collect a patient’s own T cells, genetically modify and expand them outside the body, and then infuse the cells back into the patient. CLDN18.2 is expressed on some gastric cancer cells, making it a target that CAR-T cells can recognize. However, the dense tissue, immunosuppressive microenvironment, and antigen heterogeneity of solid tumors have long hindered the cells from entering tumors and maintaining their activity.

To address this barrier, satri-cel’s pre-infusion conditioning regimen adds low-dose albumin-bound paclitaxel to cyclophosphamide and fludarabine. The developer says the regimen is designed to promote CAR-T infiltration and enhance antitumor activity. However, more clinical data are still needed to determine how much each individual component contributes to the overall efficacy.

The approval was supported in part by a randomized phase 2 trial led by researchers at Peking University Cancer Hospital and published in *The Lancet*. AABB’s review of the case noted that satri-cel improved progression-free survival compared with treatment selected by physicians. Available source summaries do not fully report overall survival, the long-term duration of response, or the various types of adverse events. Whether the therapy can deliver durable and broadly reproducible clinical benefits therefore remains to be answered through longer follow-up and real-world data.

### Background

CAR-T’s success in leukemia, lymphoma, and multiple myeloma stems partly from cancer cells that are easier to reach and targets that are relatively well defined. Solid tumors are more complex: cells within the same tumor may not all carry the same antigen, and treatment pressure may also allow antigen-negative cells to survive. Satri-cel’s approval demonstrates that these barriers are not insurmountable, but it cannot be directly inferred that CAR-T has broadly overcome solid tumors.

Implementation challenges are equally real. Autologous therapies require cells to be collected and manufactured separately for each patient, placing greater demands on treatment centers, supply chains, and waiting times. According to *Caixin*, citing the company’s investor conference call, the product is priced at RMB 990,000 per infusion. Actual accessibility will also depend on payment and healthcare-system arrangements. The next critical questions are not only whether suitable targets can be found in more tumors, but also how to make these highly customized therapies safe, affordable, and consistently available.